Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs TeraWulf Inc (WULF) Price & Performance

ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.

Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.

WULF trades at $21.97, down 5.3% today, amid a bearish technical signal. The stock shows extreme valuation ratios with a P/S of 53.26 and P/B of 84.25, while profitability metrics are deeply negative, including a net income margin of -611.46%. Recent news highlights a major $19 billion, 20-year contract with Anthropic for AI data center infrastructure, signaling a strategic pivot but also high capital expenditure requirements.

The outlook is bifurcated: strong analyst buy consensus and the Anthropic deal offer long-term growth potential in AI infrastructure, but near-term risks include persistent losses, high debt, and execution challenges. Investors face volatility from operational cash burn and market sentiment shifts around AI stocks.